CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications
Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.
The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.
CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials.
Investment and Licensing (In/Out) Opportunity 1: Name
Experienced Vice President Of Business Development with a demonstrated history of working in the pharmaceuticals industry. Skilled in Medical Devices, Biotechnology, Fundraising, Biomedical Engineering, and Start-ups. Strong sales professional
Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.
Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.
This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.
Diane Abensur is a Franco-Israeli entrepreneur and the CEO & co-founder of Nanosynex. She established the company in 2017 after graduating from the Technion Institute of Technology International M.B.A (Haifa, Israel). She graduated from E.D.H.E.C Business School (Lille, France) and obtained her Master Degree in Business Management. In between, she worked as a junior analyst in consulting and M&A on healthcare deals in Paris and New York.
Oxyprem
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
RetinAI Medical is a Swiss company that supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence (AI). Our vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma.
Our solutions rely on the latest advances in medical image analysis, ophthalmology and machine learning. We have a unique team of scientists working to fully realize the capabilities of AI, and to integrate this technology into the next generation of medical devices.
Scailyte AG is an innovative Swiss-based company developing artificial intelligence (AI) technology for clinical research and diagnostics. We are offering a unique solution for the discovery of novel biomarkers for ultra-sensitive and early diagnosis of complex diseases such as cancer.
Responsive Web Design powered by 